173 related articles for article (PubMed ID: 23082133)
1. Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial.
Baker JV; Huppler Hullsiek K; Prosser R; Duprez D; Grimm R; Tracy RP; Rhame F; Henry K; Neaton JD
PLoS One; 2012; 7(10):e46894. PubMed ID: 23082133
[TBL] [Abstract][Full Text] [Related]
2. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial.
Weiss RJ; Stapff M; Lin Y
Am J Cardiovasc Drugs; 2013 Apr; 13(2):129-40. PubMed ID: 23519546
[TBL] [Abstract][Full Text] [Related]
3. Effect of combining ACE inhibitor and statin in severe experimental nephropathy.
Zoja C; Corna D; Rottoli D; Cattaneo D; Zanchi C; Tomasoni S; Abbate M; Remuzzi G
Kidney Int; 2002 May; 61(5):1635-45. PubMed ID: 11967013
[TBL] [Abstract][Full Text] [Related]
4. Effect of the HMG-CoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia.
Glorioso N; Troffa C; Filigheddu F; Dettori F; Soro A; Parpaglia PP; Collatina S; Pahor M
Hypertension; 1999 Dec; 34(6):1281-6. PubMed ID: 10601131
[TBL] [Abstract][Full Text] [Related]
5. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction.
Wald DS; Law M; Mills S; Bestwick JP; Morris JK; Wald NJ
Clin Ther; 2008 Nov; 30(11):2030-9. PubMed ID: 19108791
[TBL] [Abstract][Full Text] [Related]
6. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial.
Thom S; Poulter N; Field J; Patel A; Prabhakaran D; Stanton A; Grobbee DE; Bots ML; Reddy KS; Cidambi R; Bompoint S; Billot L; Rodgers A;
JAMA; 2013 Sep; 310(9):918-29. PubMed ID: 24002278
[TBL] [Abstract][Full Text] [Related]
7. Low-Density Lipoprotein Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men With Primary Elevations of Low-Density Lipoprotein Cholesterol Levels of 190 mg/dL or Above: Analyses From the WOSCOPS (West of Scotland Coronary Prevention Study) 5-Year Randomized Trial and 20-Year Observational Follow-Up.
Vallejo-Vaz AJ; Robertson M; Catapano AL; Watts GF; Kastelein JJ; Packard CJ; Ford I; Ray KK
Circulation; 2017 Nov; 136(20):1878-1891. PubMed ID: 28877913
[TBL] [Abstract][Full Text] [Related]
8. Estimated cardiovascular relative risk reduction from fixed-dose combination pill (polypill) treatment in a wide range of patients with a moderate risk of cardiovascular disease.
Lafeber M; Webster R; Visseren FLj; Bots ML; Grobbee DE; Spiering W; Rodgers A;
Eur J Prev Cardiol; 2016 Aug; 23(12):1289-97. PubMed ID: 26743587
[TBL] [Abstract][Full Text] [Related]
9. Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study.
Mallon PW; Miller J; Kovacic JC; Kent-Hughes J; Norris R; Samaras K; Feneley MP; Cooper DA; Carr A
AIDS; 2006 Apr; 20(7):1003-10. PubMed ID: 16603852
[TBL] [Abstract][Full Text] [Related]
10. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
Albert MA; Danielson E; Rifai N; Ridker PM;
JAMA; 2001 Jul; 286(1):64-70. PubMed ID: 11434828
[TBL] [Abstract][Full Text] [Related]
11. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
Black HR; Graff A; Shute D; Stoltz R; Ruff D; Levine J; Shi Y; Mallows S
J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
[TBL] [Abstract][Full Text] [Related]
12. Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril).
Spósito AC; Mansur AP; Coelho OR; Nicolau JC; Ramires JA
Am J Cardiol; 1999 May; 83(10):1497-9, A8. PubMed ID: 10335771
[TBL] [Abstract][Full Text] [Related]
13. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors.
Stein JH; Merwood MA; Bellehumeur JL; Aeschlimann SE; Korcarz CE; Underbakke GL; Mays ME; Sosman JM
Am Heart J; 2004 Apr; 147(4):E18. PubMed ID: 15077088
[TBL] [Abstract][Full Text] [Related]
14. Lisinopril reduces albuminuria during exercise in low grade microalbuminuric type 1 diabetic patients: a double blind randomized study.
Poulsen PL; Ebbehøj E; Mogensen CE
J Intern Med; 2001 May; 249(5):433-40. PubMed ID: 11350567
[TBL] [Abstract][Full Text] [Related]
15. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
JAMA; 2002 Dec; 288(23):2998-3007. PubMed ID: 12479764
[TBL] [Abstract][Full Text] [Related]
16. Effect of fixed dose combination treatment on adherence and risk factor control among patients at high risk of cardiovascular disease: randomised controlled trial in primary care.
Selak V; Elley CR; Bullen C; Crengle S; Wadham A; Rafter N; Parag V; Harwood M; Doughty RN; Arroll B; Milne RJ; Bramley D; Bryant L; Jackson R; Rodgers A
BMJ; 2014 May; 348():g3318. PubMed ID: 24868083
[TBL] [Abstract][Full Text] [Related]
17. Reduction in blood pressure with statins: results from the UCSD Statin Study, a randomized trial.
Golomb BA; Dimsdale JE; White HL; Ritchie JB; Criqui MH
Arch Intern Med; 2008 Apr; 168(7):721-7. PubMed ID: 18413554
[TBL] [Abstract][Full Text] [Related]
18. Effects of manidipine and its combination with an ACE inhibitor on insulin sensitivity and metabolic, inflammatory and prothrombotic markers in hypertensive patients with metabolic syndrome: the MARCADOR study.
Martinez-Martin FJ; Macias-Batista A; Comi-Diaz C; Rodriguez-Rosas H; Soriano-Perera P; Pedrianes-Martin P
Clin Drug Investig; 2011; 31(3):201-12. PubMed ID: 21155616
[TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.
Tani S; Nagao K; Hirayama A
Am J Cardiovasc Drugs; 2011 Dec; 11(6):411-7. PubMed ID: 22149320
[TBL] [Abstract][Full Text] [Related]
20. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.
Asselbergs FW; Diercks GF; Hillege HL; van Boven AJ; Janssen WM; Voors AA; de Zeeuw D; de Jong PE; van Veldhuisen DJ; van Gilst WH;
Circulation; 2004 Nov; 110(18):2809-16. PubMed ID: 15492322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
